Serotonin (5-HT) plays a central role in the integrity of different brain functions. The 5-HT homeostasis is regulated by many factors, including serotonin transporter (SERT), monoamine oxidase enzyme (MAO), and several 5-HT receptors, including the 5-HT1B. There is little knowledge how the dynamics of this system is affected by the amyloid-β (Aβ) burden of Alzheimer’s disease (AD) pathology. SH-SY5Y neuroblastoma cells transfected with the amyloid precursor protein (APP) gene containing the Swedish mutations causing familial AD (APPswe), were used as a model to explore the effect of Aβ pathology on 5-HT1B and related molecules including the receptor adaptor protein (p11), SERT and MAOA gene expression, and MAOA activity after treatment with selective serotonin reuptake inhibitor (SSRI) (sertraline), and a 5-HT1B receptor antagonist. Sertraline led more than 70 fold increase of 5-HT1B gene expression (p < 0.001), an increased serotonin turnover in both APPswe and control cells and reduced intracellular serotonin levels by 75% in APPswe cells but not in controls (p > 0.05). Treatment with the 5-HT1B receptor antagonist increased SERT gene-expression in control cells but not in the APPswe cells. 5-HT and 5-HT1B antagonist treatment resulted in different p11 expression patterns in APPswe cells compared to controls. Although MAOA gene expression was not changed by APPswe overexpression, adding 5-HT lead to a significant increase in MAOA gene expression in APPswe but not control cells. These findings suggest that the sensitivity of the 5-HT1B receptor and related systems is affected by APPswe overexpression, with potential relevance for pharmacologic intervention in AD. This may at least partly explain the lack of effect of SSRIs in patients with AD and depression.
FullerRW (1996) Mechanisms and functions of serotonin neuronal systems: Opportunities for neuropeptide interactions. Ann N Y Acad Sci780, 176–184.
2.
RodriguezJJ, NoristaniHN, VerkhratskyA (2012) The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol99, 15–41.
3.
ZhouL, HuangKX, KecojevicA, WelshAM, KoliatsosVE (2006) Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem96, 396–406.
4.
HaganCE, McDevittRA, LiuYS, FurayAR, NeumaierJF (2012) 5-HT1B autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse66, 1024–1034.
5.
DawsLC, GouldGG, TeicherSD, GerhardtGA, FrazerS (2000) 5-HT1B receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J Neurochem75, 2113–2122.
6.
Garcia-AllozaM, HirstWD, ChenCP, LasherasB, FrancisPT, RamirezMJ (2004) Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology29, 410–416.
7.
SvenningssonP, CherguiK, RachleffI, FlajoletM, ZhangX, El YacoubiM, VaugeoisJM, NomikosGG, GreengardP (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science311, 77–80.
8.
Warner-SchmidtJL, FlajoletM, MallerA, ChenEY, QiH, SvenningssonP, GreengardP (2009) Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci29, 1937–1946
.
9.
SvenningssonP, KimY, Warner-SchmidtJ, OhYS, GreengardP (2013) p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci14, 673–680.
NeumaierJF, RootDC, HamblinMW (1996) Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology15, 515–522.
12.
NorumJH, HartK, LevyFO (2003) Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J Biol Chem278, 3098–3104.
13.
MendezJ, KadiaTM, SomayazulaRK, El-BadawiKI, CowenDS (1999) Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. J Neurochem73, 162–168.
14.
MenesesA (2001) Could the 5-HT1B receptor inverse agonism affect learning consolidation?. Neurosci Biobehav Rev25, 193–201.
15.
BuhotMC, PatraSK, NailiS (1995) Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat. Eur J Pharmacol285, 221–228.
Chartier-HarlinMC, CrawfordF, HouldenH, WarrenA, HughesD, FidaniL, GoateA, RossorM, RoquesP, HardyJ, MullanM (1991) Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature353, 844–846.
22.
RamirezMJ, LaiMK, TorderaRM, FrancisPT (2014) Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: Rationale and current status. Drugs74, 729–736.
23.
LiuY, YooMJ, SavonenkoA, StirlingW, PriceDL, BorcheltDR, MamounasL, LyonsWE, BlueME, LeeMK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci28, 13805–13814.
24.
Garcia-AllozaM, Gil-BeaFJ, Diez-ArizaM, ChenCPLH, FrancisPT, LasherasB, RamirezMJ (2005) Cholinergic-serotonergic imbalance contributes to cognitive and behoral symptoms in Alzheimer’s disease. Neuropsychologia43, 442–449.
25.
TohgiH, AbeT, TakahashiS, KimuraM, TakahashiJ, KikuchiT (1992) Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci Lett141, 9–12.
26.
AarslandD, SharpS, BallardC (2005) Psychiatric and behoral symptoms in Alzheimer’s disease and other dementias: Etiology and management. Curr Neurol Neurosci Rep5, 345–354.
MullanM, CrawfordF, AxelmanK, HouldenH, LiliusL, WinbladB, LannfeltL (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet1, 345–347.
29.
TajeddinnW, PerssonT, MaioliS, Calvo-GarridoJ, Parrado-FernandezC, YoshitakeT, KehrJ, FrancisP, WinbladB, HoglundK, Cedazo-MinguezA, AarslandD (2015) 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett594, 137–143.
MaioliS, PuertaE, Merino-SerraisP, FusariL, Gil-BeaF, RimondiniR, Cedazo-MinguezA (2012) Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice. J Alzheimers Dis32, 341–355.
32.
LarionovA, KrauseA, MillerW (2005) A standard curve based method for relative real time PCR data processing. BMC Bioinformatics6, 62.
33.
VandesompeleJ, De PreterK, PattynF, PoppeB, Van RoyN, De PaepeA, SpelemanF (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol3, Research0034.
34.
YueCT, LiuYL (2005) Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells. Cell Biochem Funct23, 109–114.
35.
KarakhanovaS, GolovastovaM, PhilippovPP, WernerJ, BazhinAV (2014) Interlude of cGMP and cGMP/protein kinase G type 1 in pancreatic adenocarcinoma cells. Pancreas43, 784–794.
36.
PullarkatSR, MyselsDJ, TanM, CowenDS (1998) Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems. J Neurochem71, 1059–1067.
37.
SinghR, RamakrishnaR, BhateriaM, BhattaRS (2014) In vitro evaluation of Bacopa monniera extract and individual constituents on human recombinant monoamine oxidase enzymes. Phytother Res28, 1419–1422.
FaganAM, MintunMA, ShahAR, AldeaP, RoeCM, MachRH, MarcusD, MorrisJC, HoltzmanDM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med1, 371–380.
41.
CirritoJR, DisabatoBM, RestivoJL, VergesDK, GoebelWD, SathyanA, HayrehD, D’AngeloG, BenzingerT, YoonH, KimJ, MorrisJC, MintunMA, ShelineYI (2011) Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A108, 14968–14973.
42.
ShelineYI, WestT, YarasheskiK, SwarmR, JasielecMS, FisherJR, FickerWD, YanP, XiongC, FrederiksenC, GrzelakMV, ChottR, BatemanRJ, MorrisJC, MintunMA, LeeJM, CirritoJR (2014) An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med6, 236re234.
43.
GasterLM, BlaneyFE, DaviesS, DuckworthDM, HamP, JenkinsS, JenningsAJ, JoinerGF, KingFD, MulhollandKR, WymanPA, HaganJJ, HatcherJ, JonesBJ, MiddlemissDN, PriceGW, RileyG, RobertsC, RoutledgeC, SelkirkJ, SladePD (1998) The selective 5-HT1B receptor inverse agonist 1’-methyl-5-[[2’-methyl-4’-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4’-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor 762 function both in vitro and in vivo. J Med Chem41, 1218–1235.
